Current status and recommendations for biomarkers and biobanking in neurofibromatosis

Neurology

Volumn 87, Issue 7, 2016, Pages S40-S48

  Hanemann, C Oliver ^a   Blakeley, Jaishri O ^b   Nunes, Fabio P ^c,d   Robertson, Kent ^c   Stemmer Rachamimov, Anat ^e   Mautner, Victor ^f   Kurtz, Andreas ^g,h   Ferguson, Michael ^c   Widemann, Brigitte C ⁱ   Evans, D Gareth ^j   Ferner, Rosalie ^k   Carroll, Steven L ^l   Korf, Bruce ^m   Wolkenstein, Pierre ⁿ   Knight, Pamela ^o   Plotkin, Scott R ^e  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h Seoul National University   (South Korea)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^l MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ GHU Henri Mondor   (France)

^o Children's Tumor Foundation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MERLIN; NEUROFIBROMIN; SCHWANNOMATOSIS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOBANK; CLINICAL OUTCOME; HUMAN; NEUROFIBROMATOSIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; CONSENSUS DEVELOPMENT; INFORMATION PROCESSING; METABOLISM; NEURILEMMOMA; NEUROFIBROMATOSES; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; PRACTICE GUIDELINE; SKIN NEOPLASMS;

BIOLOGICAL SPECIMEN BANKS; BIOMARKERS; DATASETS AS TOPIC; HUMANS; NEURILEMMOMA; NEUROFIBROMATOSES; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; SKIN NEOPLASMS;

EID: 85003422211     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002932     Document Type: Article

References (22)

1. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358-367.
2. Plotkin SR, Blakeley JO, Dombi E, et al. Achieving consensus for clinical trials: The REiNS International Collaboration. Neurology 2013;81:S1-S5.
3. Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 2013;81: S33-S40.
4. Khleif SN, Doroshow JH, Hait WN; AACR-FDA-NCI Cancer Biomarkers Collaborative. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010;16:3299-3318.
5. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: A twenty first century perspective. Lancet Neurol 2007;6:340-351.
6. Lloyd SK, Evans DG. Neurofibromatosis type 2 (NF2): diagnosis and management. Handb Clin Neurol 2013; 115:957-967.
7. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44:81-88.
8. Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007;61:189-198.
9. Kolanczyk M, Mautner V, Kossler N, et al. MIA is a potential biomarker for tumour load in neurofibromatosis type 1. BMC Med 2011;9:82.
10. Yoshida Y, Furumura M, Tahira M, Horie T, Yamamoto O. Serum biomarker in neurofibromatosis type 1. J Dermatol Sci 2012;67:155-158.
11. Hummel TR, Jessen WJ, Miller SJ, et al. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res 2010;16: 5048-5057.
12. Jensen CH, Schroder HD, Teisner B, Laursen I, Brandrup F, Rasmussen HB. Fetal antigen 1, a member of the epidermal growth factor superfamily, in neurofibromas and serum from patients with neurofibromatosis type 1. Br J Dermatol 1999;140:1054-1059.
13. Johansson G, Peng PC, Huang PY, et al. Soluble AXL: A possible circulating biomarker for neurofibromatosis type 1 related tumor burden. PLoS One 2014;9:e115916.
14. Park SJ, Sawitzki B, Kluwe L, Mautner VF, Holtkamp N, Kurtz A. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med 2013;11:109.
15. Danielsen SA, Lind GE, Kolberg M, et al. Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. Neuro Oncol 2015;17:63-69.
16. Gong M, Ma J, Li M, Zhou M, Hock JM, Yu X. MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors. Neuro Oncol 2012;14:1007-1017.
17. Yu J, Deshmukh H, Payton JE, et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res 2011;17:1924-1934.
18. Mohan P, Castellsague J, Jiang J, et al. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. Oncotarget 2013;4:80-93.
19. Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. Oncologist 2014;19: 193-201.
20. Kolberg M, Holand M, Lind GE, et al. Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours: A prognostic test after surgical resection. Mol Oncol 2015;9:1129-1139.
21. Blakeley JO, Ye X, Duda DG, et al. Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol 2016;34:1669-1675.
22. Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Zheng PP. Circulating glioma biomarkers. Neuro Oncol 2015;17:343-360.